Pathogenetic treatment of the patient with splenic marginal zone lymphoma complicated by Evans syndrome

N A Romanenko; S S Bessmeltsev; K M Abdulkadyrov

doi:10.17816/KMJ1726

Kazan medical journal ›› 2012, Vol. 93 ›› Issue (5) : 843 -846. DOI: 10.17816/KMJ1726

Clinical observations

research-article

Pathogenetic treatment of the patient with splenic marginal zone lymphoma complicated by Evans syndrome

Author information +

History +

PDF

Abstract

A case report of a patients with splenic marginal zone lymphoma, in whom clinical remission was initially achieved by 5 continuous courses of combined treatment with fludarabine 25 mg/m2 and cyclophosphamide 350 mg/m2 at days 1-3. Nevertheless, 6 months after patient developed a clinical picture of Evans syndrome, characterized by severe hemolytic anemia, thrombocytopenia and neutropenia. Corticosteroid treatment accompanied by blood transfusion was initiated, the effect was marginal and short-lasting. Switch to rituximab monotherapy allowed to archieve complete clinical and hematological remission with full blood count parameters reversal.

Keywords

splenic marginal zone lymphoma / anemia / thrombocytopenia / red blood cells transfusion / erythropoietin alpha / Evans syndrome / rituximab / CD20 antibodies

Cite this article

Download citation ▾

N A Romanenko, S S Bessmeltsev, K M Abdulkadyrov. Pathogenetic treatment of the patient with splenic marginal zone lymphoma complicated by Evans syndrome. Kazan medical journal, 2012, 93(5): 843-846 DOI:10.17816/KMJ1726

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Поддубная И.В. Неходжкинские лимфомы. Клиническая онкогематология. Руководство для врачей / Под ред. М.А. Волковой. - М.: Медицина, 2007. - С. 724-770.

[2]	Debiasi M., Hehnemann M., Garicochea B. Rituximab monotherapy for splenic marginal zone lymphoma with villous lymphocytes: report on long-term disease control for two patients with recurrence after splenectomy // Sao Paulo Med. J. - 2010. - Vol. 128, suppl. 6. - P. 375-377.

[3]	García-Muñoz R., Rodriguez-Otero P., Pegenaute C. et al. Splenic marginal zone lymphoma with Evans’ syndrome, autoimmunity, and peripheral gamma/delta T cells // Ann. Hematol. - 2009. - Vol. 88, N 2. - P. 177-178.

[4]	Kojima M., Sato E., Oshimi K. et al. Characteristics of CD5-positive splenic marginal zone lymphoma with leukemic manifestation; clinical, flow cytometry, and histopathological findings of 11 cases // J. Clin. Exp. Hematop. - 2010. - Vol. 50, N 2. - P. 107-112.

[5]	Martin P., Rutherford S., Leonard J.P. Splenic lymphomas: is there still a role for splenectomy? // Oncology (Williston Park). - 2012. - Vol. 26, N 2. - P. 204-206.

[6]	Michel M. Characteristics of warm autoimmune hemolytic anemia and Evans syndrome in adults // Press Med. - 2008. - Vol. 37, N 9. - P. 1309-1318.

[7]	Piris M.A., Arribas A., Mollejo M. Marginal zone lymphoma // Semin. Diagn. Pathol. - 2011. - Vol. 28, N 2. - P. 135-145.

[8]	Thieblemont C., Davi F., Noguera M.E. et al. Splenic marginal zone lymphoma: current knowledge and future directions // Oncology (Williston Park). - 2012. - Vol. 26, N 2. - P. 194-202.